How Low Can AbbVie Stock Really Go?
AbbVie (ABBV) faces a recent stock dip amid broader market gains, yet its immunology engine and robust dividend outlook signal long-term strength. But as investors weigh near-term market shifts, it’s worth asking: can ABBV navigate cyclical pressures and maintain its growth trajectory?
Before judging its downturn reslience, let’s look at where AbbVie stands today.
- Size: AbbVie is a $389 Bil company with $60 Bil in revenue currently trading at $220.18.
- Fundamentals: Last 12 month revenue growth of 7.4% and operating margin of 24.1%.
- Liquidity: Has Debt to Equity ratio of 0.18 and Cash to Assets ratio of 0.04
- Valuation: AbbVie stock is currently trading at P/E multiple of 163.1 and P/EBIT multiple of 85.8
- Has one instance since 2010 where it dipped >30% in < 30 days and subsequently returned 71.2% within a year. See ABBV Dip Buy Analysis.
These metrics point to a Moderate operational performance, alongside Moderate valuation – making the stock Fairly Priced. For details, see Buy or Sell ABBV Stock
That brings us to the key consideration for investors looking to add ABBV to their portfolio: how resilient is ABBV stock if markets turn south? This is where our downturn resilience framework comes in. Suppose ABBV stock falls 20-30% to $154 – can investors comfortably hold on? Turns out, the stock has fared worse than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
- How to Get Paid to Buy ORCL at a Steep Discount
- Where Could The Next Breakout for Boeing Stock Come From
- The Hidden Dangers Facing RTX Stock
- Could Freshworks Stock’s Cash Flow Spark the Next Rally?
- Caterpillar Stock On A Winning Streak: Time To Get In Or Book Profits?
- Is Newmont Stock Poised for a Rally?
2022 Inflation Shock
- ABBV stock fell 23.3% from a high of $174.96 on 8 April 2022 to $134.21 on 30 September 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 7 February 2024
- Since then, the stock increased to a high of $244.38 on 1 October 2025 , and currently trades at $220.18
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -23.3% | -25.4% |
| Time to Full Recovery | 495 days | 464 days |
2020 Covid Pandemic
- ABBV stock fell 34.0% from a high of $97.79 on 12 February 2020 to $64.50 on 23 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 30 June 2020
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -34.0% | -33.9% |
| Time to Full Recovery | 99 days | 148 days |
2018 Correction
- ABBV stock fell 48.9% from a high of $123.21 on 26 January 2018 to $62.98 on 15 August 2019 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 9 December 2021
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -48.9% | -19.8% |
| Time to Full Recovery | 847 days | 120 days |
Feeling jittery about ABBV stock? Consider portfolio approach.
A Multi Asset Portfolio Beats Picking Stocks Alone
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices